Hochschulschrift
Targeted transduction of T cell subsets for immunotherapy of cancer and infectious disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Berlin, Humboldt Universität zu Berlin, Dissertation, 2016
- Schlagwort
-
Immunologie
Immunsystem
Lymphozyt
Leukozyt
Immunität
Resistenz
Immunchemie
- Ereignis
-
Veröffentlichung
- (wo)
-
Berlin
- (wer)
-
Lebenswissenschaftliche Fakultät
- (wann)
-
2016
- Urheber
- Beteiligte Personen und Organisationen
-
Uckert, Wolfgang
Pezzutto, Antonio
Buchholz, Christian
- URN
-
urn:nbn:de:kobv:11-100243313
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:50 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Objekttyp
- Hochschulschrift
Beteiligte
- Edes, Inan
- Uckert, Wolfgang
- Pezzutto, Antonio
- Buchholz, Christian
- Lebenswissenschaftliche Fakultät
Entstanden
- 2016
Ähnliche Objekte (12)
Signal transduction and targeted therapy
Targeted interference with signal transduction events
Essential and complementary function of dendritic cell subsets during immunotherapy
Identification of Suitable T-Cell Subsets for Personalized Antiviral T-Cell Immunotherapy
Microarray-based multicycle-enrichment of genomic subsets for targeted next-generation sequencing
Targeted gene transfer to enhance safety and efficacy of immunotherapy
Combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy
Entry targeted lentiviral vectors for the specific modification of distinct subsets of immune cells
Entry targeted lentiviral vectors for the specific modification of distinct subsets of immune cells
Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies
Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy
Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma
Signal transduction and targeted therapy
Targeted interference with signal transduction events
Essential and complementary function of dendritic cell subsets during immunotherapy
Identification of Suitable T-Cell Subsets for Personalized Antiviral T-Cell Immunotherapy
Microarray-based multicycle-enrichment of genomic subsets for targeted next-generation sequencing
Targeted gene transfer to enhance safety and efficacy of immunotherapy
Combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy
Entry targeted lentiviral vectors for the specific modification of distinct subsets of immune cells
Entry targeted lentiviral vectors for the specific modification of distinct subsets of immune cells
Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies
Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy
Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma
Signal transduction and targeted therapy
Targeted interference with signal transduction events
Essential and complementary function of dendritic cell subsets during immunotherapy
Identification of Suitable T-Cell Subsets for Personalized Antiviral T-Cell Immunotherapy
Microarray-based multicycle-enrichment of genomic subsets for targeted next-generation sequencing
Targeted gene transfer to enhance safety and efficacy of immunotherapy
Combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy
Entry targeted lentiviral vectors for the specific modification of distinct subsets of immune cells
Entry targeted lentiviral vectors for the specific modification of distinct subsets of immune cells
Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies
Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy